Cisplatin/Etoposide or Paclitaxel/Carboplatin with Concurrent Radiation Therapy in Stage IIIB Non-Small Cell Lung Cancer: A One-Year Randomized Trial at a Low-Resource Setting
- Conditions
- C34.9Bronchus or lung, unspecified
- Registration Number
- DRKS00012599
- Lead Sponsor
- Oncology & Radiotherapy Centre, Square Hospitals Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion criteria included Non-small cell lung cancer proved by pathology or cytology; inoperable AJCC stage IIIB prior to the initiation of treatment; age: 18 to 75; Eastern Cooperative Oncology Group (ECOG) performance status =2; lose of weight <10% during 6 months; biochemical tests values: WBC =3.5×109/L, neutrophils =1.5×109/L, platelets =100×109/L, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin =1.5 × the upper limit of the institutional normal range; creatinine concentration =120 umol/L, and creatinine clearance=50 ml/min; no serious diseases of important organs; written informed consent signed prior to enrollment.
Exclusion Criteria included pretreatment with radiotherapy, chemotherapy or biological agents; pregnant or lactating woman; serious diseases (include significant cardiovascular disease or uncontrolled diabetes) of important organs; other malignancies; active uncontrolled infection; joined in other clinical trial.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method